Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years

Introduction: The Human T-lymphotropic virus type 1 (HTLV-1) was the first described human retrovirus. It is currently estimated that around 5 to 10 million people worldwide are infected with this virus. Despite its high prevalence, there is still no preventive vaccine against the HTLV-1 infection. It is known that vaccine development and large-scale immunization play an important role in global public health. To understand the advances in this field we performed a systematic review regarding the current progress in the development of a preventive vaccine against the HTLV-1 infection.Methods: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA (R)) guidelines and was registered at the International Prospective Register of Systematic Reviews (PROSPERO). The search for articles was performed in PubMed, Lilacs, Embase and SciELO databases. From the 2,485 articles identified, 25 were selected according to the inclusion and exclusion criteria.Results: The analysis of these articles indicated that potential vaccine designs in development are available, although there is still a paucity of studies in the human clinical trial phase.Discussion: Although HTLV-1 was discovered almost 40 years ago, it remains a great challenge and a worldwide neglected threat. The scarcity of funding contributes decisively to the inconclusiveness of the vaccine development. The data summarized here intends to highlight the necessity to improve the current knowledge of this neglected retrovirus, encouraging for more studies on vaccine development aiming the to eliminate this human threat.

Automated summary

The Human T-lymphotropic virus type 1 (HTLV-1) is the first human retrovirus described and currently infects around 5 to 10 million people worldwide. Despite its high prevalence, there is still no preventive vaccine against HTLV-1 infection. This systematic review analyzed 25 selected articles and found that although potential vaccine designs are available, there is a lack of studies in the human clinical trial phase.